160 related articles for article (PubMed ID: 11920750)
1. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
Khoo SM; Prankerd RJ; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2002 Mar; 91(3):647-59. PubMed ID: 11920750
[TBL] [Abstract][Full Text] [Related]
2. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Khoo SM; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
[TBL] [Abstract][Full Text] [Related]
3. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Humberstone AJ; Porter CJ; Charman WN
J Pharm Sci; 1996 May; 85(5):525-9. PubMed ID: 8742945
[TBL] [Abstract][Full Text] [Related]
4. Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: Effects on its apparent ionization constant.
Taillardat-Bertschinger A; Perry CS; Galland A; Prankerd RJ; Charman WN
J Pharm Sci; 2003 Nov; 92(11):2217-28. PubMed ID: 14603507
[TBL] [Abstract][Full Text] [Related]
5. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.
Porter CJ; Charman SA; Humberstone AJ; Charman WN
J Pharm Sci; 1996 Apr; 85(4):357-61. PubMed ID: 8901068
[TBL] [Abstract][Full Text] [Related]
6. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?
Shackleford DM; Porter CJ; Charman WN
Biopharm Drug Dispos; 2003 May; 24(4):153-7. PubMed ID: 12698498
[TBL] [Abstract][Full Text] [Related]
7. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN
Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.
Holm R; Müllertz A; Pedersen GP; Kristensen HG
Pharm Res; 2001 Sep; 18(9):1299-304. PubMed ID: 11683243
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Porter CJ; Charman SA; Charman WN
J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
[TBL] [Abstract][Full Text] [Related]
10. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623).
Trevaskis NL; McEvoy CL; McIntosh MP; Edwards GA; Shanker RM; Charman WN; Porter CJ
Pharm Res; 2010 May; 27(5):878-93. PubMed ID: 20221896
[TBL] [Abstract][Full Text] [Related]
11. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
[TBL] [Abstract][Full Text] [Related]
12. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
[TBL] [Abstract][Full Text] [Related]
14. Determination of physicochemical properties of halofantrine.
Babalola CP; Adegoke AO; Ogunjinmi MA; Osimosu MO
Afr J Med Med Sci; 2003 Dec; 32(4):357-9. PubMed ID: 15259917
[TBL] [Abstract][Full Text] [Related]
15. A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.
Trevaskis NL; Caliph SM; Nguyen G; Tso P; Charman WN; Porter CJ
Pharm Res; 2013 Dec; 30(12):3254-70. PubMed ID: 23430484
[TBL] [Abstract][Full Text] [Related]
16. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats.
Holm R; Müllertz A; Christensen E; Høy CE; Kristensen HG
Eur J Pharm Sci; 2001 Dec; 14(4):331-7. PubMed ID: 11684408
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.
Khoo SM; Porter JH; Edwards GA; Charman WN
J Pharm Sci; 1998 Dec; 87(12):1538-41. PubMed ID: 10189263
[TBL] [Abstract][Full Text] [Related]
18. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
Caliph SM; Trevaskis NL; Charman WN; Porter CJ
J Pharm Sci; 2012 Sep; 101(9):3540-6. PubMed ID: 22623170
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
Porter CJ; Kaukonen AM; Taillardat-Bertschinger A; Boyd BJ; O'Connor JM; Edwards GA; Charman WN
J Pharm Sci; 2004 May; 93(5):1110-21. PubMed ID: 15067688
[TBL] [Abstract][Full Text] [Related]
20. Lipid-based formulations for intestinal lymphatic delivery.
O'Driscoll CM
Eur J Pharm Sci; 2002 Jun; 15(5):405-15. PubMed ID: 12036717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
